Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 66

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 66
---
,000 |
| Additional retainer for compensation committee member              |     |              |  5,000 |
| Additional retainer for nominating and governance committee chair  |     |              |  8,000 |
| Additional retainer for nominating and governance committee member |     |              |  4,000 |
| Additional retainer for science and technology committee chair     |     |              |  8,000 |
| Additional retainer for science and technology committee member    |     |              |  4,000 |

**These retainers are payable in arrears in four equal quarterly installments within thirty days after the end of each calendar quarter, provided that the amount of such payment will be prorated for any portion of such quarter that the director is not serving on our board. We also reimburse our directors for their reasonable out-of-pocketexpenses in connection with attending our board and committee meetings. Equity Compensation In addition to cash compensation, each non-employeedirector is eligible to receive options under the 2020 Plan. Each option granted under the policy is a nonstatutory stock option and has an exercise price per share equal to the fair market value of a common share on the date of grant. Any options granted under this policy have a term of 10 years from the date of grant, subject to earlier termination in connection with a termination of the eligible director’s continuous service with us. Vesting schedules for equity awards are subject to the non-employeedirector’s continuous service on each applicable vesting date. Upon the termination of the membership of the non-employeedirector on the board for any reason, such director’s options granted under this policy shall remain exercisable for nine months following such director’s date of termination (or such longer period as the board may determine in its discretion on or after the date of grant of such options). Notwithstanding any vesting schedule, for each non-employeedirector who remains in continuous service with us until immediately prior to the closing of a change in control (as such term is defined in our 2020 Plan), the shares subject to such director’s then-outstanding initial or annual equity awards that were granted pursuant to this policy will become fully vested immediately prior to the closing of such change in control. Initial Award Each new non-employeedirector who first joins our board of directors will automatically, upon the date of such director’s initial election or appointment to be a non-employeedirector, be granted an initial, one-timeequity award of